All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
It doesn’t take a PhD in economics to come up with practical solutions to jumpstart our economy and create jobs. But it does take guts – and real-world vision – to implement change that makes a difference. One simple solution would be a tax break on overseas profits. As we have reported in BioWorld Today, the Freedom to Invest Act, H.R. 1834, would do just that. The bill, introduced in May, allows the repatriation of more than $1 trillion in overseas earnings at a 5.25 percent tax rate. But the Joint Committee on Taxation pooh-poohed the idea, saying it could...
A lot is on the line Thursday when the FDA's Oncologic Drugs Advisory Committee (ODAC) reviews Seattle Genetics Inc.'s Adcetris as a treatment for relapsed or refractory Hodgkin lymphoma and for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
WASHINGTON – Amid criticism that the FDA has yet to strike the right balance between risk and benefit, the agency's Janet Woodcock gave a House subcommittee a sneak peak of proposed PDUFA V enhancements that would address those concerns.
Like many biotechs these days, Idera Pharmaceuticals Inc. is feeling the pinch as a big pharma partner shifts its pipeline priorities, leaving the future of Idera's lead TLR9 compound up in the air.
Archimedes Pharma Ltd.'s Lazanda isn't the first fentanyl product to get the FDA's nod for breakthrough cancer pain, but its pain-free risk evaluation and mitigation strategy (REMS) and intranasal delivery could give it an edge in the U.S. market once it launches in the fall.
